HALFAN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALFAN is an oral small-molecule tablet approved by GSK in 1992 for an unknown indication. The mechanism of action and specific therapeutic use are not disclosed in available data.
LOE Approaching
With LOE approaching and competitive pressure at 30%, commercial teams face significant margin pressure and likely workforce optimization in the coming 2–3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's late-stage lifecycle; roles existing on this asset are focused on defending market share, managing generic transition, and winding down operations. Career advancement opportunities are minimal; this is a consolidation/transition role, not a growth opportunity.
Brand ManagerField Sales Representative
Worked on HALFAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.